Your new post is loading...
AbstractMulti-agent chemotherapy is the standard treatment for most B cell malignancies. Since chemotherapy can be associated with significant toxicity and since relapses resistant to chemotherapy often develop, new therapies are needed. Blinatumomab (AMG 103 or MT103) is a late-stage candidate in clinical development, which belongs to a novel class of antibody constructs termed bi-specific T cell engager antibodies. This antibody construct has dual specificity for CD19 and CD3 and can re-direct polyclonal cytotoxic T lymphocytes toward the tumor. This review focuses on the pre-clinical and clinical development of blinatumomab as a powerful new tool in the treatment of B cell malignancies.
Via Krishan Maggon
Int. Immunol. (2015) 27 (1): 31-37 doi:10.1093/intimm/dxu089
Correspondence to: Z. Zimmerman, One Amgen Center Drive, MS 38-B-A, Thousand Oaks, CA 91320, USA; E-mail: zacharyz@amgen.com